Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Dimitris Mavrudis, MD
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer
This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab combination, administered biweekly, as salvage treatment in patients with metastatic and HER2 n...
Country
Greece
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
The combination of docetaxel+epirubicin is highly effective and well tolerated as first line treatment in patients with metastatic breast cancer (MBC). Capecitabine is an active drug in wo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Anthracycline-containing regimens are recommended as adjuvant treatment for women with node positive breast cancer. In at least three large randomized clinical trials the addition or seque...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
DOXORUBICIN is recognized as one of the most active drugs for breast cancer, but its clinical utility is limited because of a cumulative dose-dependent cardiac myopathy that can lead to po...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Myocet Plus Endoxan for Older Patients With Breast Cancer
This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
In this trial investigators propose to assess the dose dense, G-CSF supported sequential administration of 4 cycles of FEC followed by 4 cycles of docetaxel versus 6 cycles of docetaxel/cy...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
The optimal treatment for pretreated patients with metastatic breast cancer has not been established. Gemcitabine and capecitabine are two active agents in this setting. For women with Her...
Country
Greece
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of metronomic oral vinorelbine taken three times a week plus daily lapatinib without break, as salvage treatment in patient...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
This study will evaluate the efficacy, safety and effect on quality of life of weekly paclitaxel plus bevacizumab as first line treatment in elderly patients (≥ 70 years old) with metastat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Dimitris Mavrudis, MD
Update Il y a 4 ans
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
This study will evaluate the efficacy of weekly paclitaxel-carboplatin combination plus bevacizumab as first line treatment in patients with metastatic triple negative breast cancer. Furth...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
Next